Status:

COMPLETED

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborating Sponsors:

Brigham and Women's Hospital

Boston Children's Hospital

Conditions:

Myelogenous Leukemia, Acute

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.

Detailed Description

Patients will receive Iressa daily until either disease progression or intolerable toxicity develops. On Day 1 of treatment, a physical exam and bloodwork will be performed. Once weekly for the first ...

Eligibility Criteria

Inclusion

  • Patients must have pathologically documented acute myelogenous leukemia and either not be a candidate for myelosuppressive chemotherapy due to age or comorbid disease; or have relapsed acute myelogenous leukemia or be refractory to standard therapy and not likely to require cytoreductive therapy within 30 days.
  • ECOG performance status 0, 1 or 2
  • Age \> 18 years
  • Adequate kidney and hepatic function
  • Greater than 4 weeks from any chemotherapy, radiotherapy, immunotherapy, or systemic steroid therapy with the exception of hydroxyurea.
  • Greater than 2 months following bone marrow or peripheral blood stem cell transplantation or donor lymphocyte infusion.

Exclusion

  • Uncontrolled active infection
  • Urgent need for cytoreductive chemotherapy, surgery, or radiotherapy
  • Current chemotherapy or chemotherapy within the last 4 weeks.
  • Pregnancy or nursing mothers
  • Infection with HIV

Key Trial Info

Start Date :

August 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2007

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT00130702

Start Date

August 1 2005

End Date

November 1 2007

Last Update

May 1 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115